Aldeyra Therapeutics, Inc.ALDX
時価総額
$3億
PER
眼科・免疫疾患向け医薬品の新興企業。従業員9名体制で外部委託を活用しreproxalapなどの候補薬の臨床開発と商業準備を展開。2019年1月の他社買収と2024年の買収候補薬開発中止。米国中心に展開。
| 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Net loss | - | - | - | - | - | -60,826,831 | -37,553,729 | -57,776,274 | -62,024,636 | -37,542,510 | -55,851,444 |
| Stock-based compensation | 2 | 2 | 3 | 3 | 4 | 8 | 7 | 7 | 8 | 6 | 8 |
| Non-cash interest expense | 150,852 | 35,829 | 27,314 | 20,341 | 59,322 | 248,567 | 566,020 | 409,471 | 331,150 | 354,193 | 177,326 |
| Net amortization of premium on marketable securities | - | - | -266,106 | -129,245 | 237,541 | 583,701 | 91,231 | - | 47,245 | 14,542 | 2 |
| Depreciation | 1,069 | 18,778 | 35,792 | 37,849 | 71,003 | 96,305 | 56,221 | 264,180 | 258,707 | 262,780 | 249,623 |
| Prepaid expenses and other current assets | 224,156 | 264,984 | -278,870 | 800,285 | 150,627 | 454,429 | 3 | -2,239,176 | 4 | -1,734,912 | -2,066,111 |
| Accounts payable | -559 | 509,866 | -575,719 | 725,522 | 2 | -2,846,142 | -426,664 | 638,064 | -886,077 | 1 | -1,157,604 |
| Accrued expenses and other liabilities | 776,613 | 291,943 | 759,822 | 290,214 | 3 | 6 | -5,006,375 | 5 | 1 | -8,078,164 | 5 |
| Deferred collaboration revenue | - | - | - | - | - | - | - | - | - | 6 | - |
| Net cash used in operating activities | - | - | - | - | -29,857,131 | -44,984,226 | -37,493,455 | -42,555,907 | -56,637,187 | -30,326,128 | -43,208,747 |
| Acquisitions of fixed assets | 14,062 | 86,119 | 11,810 | 24,759 | 262,966 | 9,529 | - | 7,806 | 16,317 | - | - |
| Purchases of marketable securities | - | - | - | - | - | - | - | - | 93 | - | 97 |
| Maturities of marketable securities | - | - | 16 | 25 | 37 | 76 | 35 | - | 63 | 30 | 52 |
| Net cash (used in) provided by investing activities | - | - | - | - | -23,335,576 | 18 | 29 | -7,806 | -29,954,530 | 30 | -44,915,755 |
| Issuance costs | - | - | - | - | - | - | - | - | - | - | 267,261 |
| Proceeds from Stock Options Exercised | - | - | - | - | - | 1 | 1 | 5 | 1 | 194,129 | 350,279 |
| Tax withholding payments for net share-settled equity awards | - | - | - | - | - | - | - | - | - | 532,951 | - |
| Proceeds from employee stock purchase plan | - | - | - | - | - | 194,849 | 126,966 | 61,529 | 96,665 | 111,102 | 38,060 |
| Debt end of term charge paid in cash | - | - | - | - | - | 123,186 | - | - | - | 1 | 292,500 |
| Net cash used in financing activities | - | - | - | - | 81 | 24 | 42 | 194 | 1 | -1,270,220 | -171,422 |
| NET DECREASE IN CASH AND CASH EQUIVALENTS | - | - | - | - | - | -2,931,642 | 33 | 152 | -85,371,625 | -1,596,348 | -88,295,924 |
| Cash paid during the period for interest | - | - | - | - | 88,963 | 238,491 | 1 | 1 | 1 | 2 | 2 |